Metal ionophores - An emerging class of anticancer drugs

IUBMB Life

Volumn 61, Issue 11, 2009, Pages 1013-1018

  Ding, Wei Qun ^a   Lind, Stuart E ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cancer; Clioquinol; Ionophore; Lysosome; Pyrithione; Pyrrolidine dithiocarbamate; Zinc

Indexed keywords

8 QUINOLINOL; ANTINEOPLASTIC AGENT; CHELATING AGENT; CLIOQUINOL; DITHIOCARBAMIC ACID DERIVATIVE; IONOPHORE; METAL; PROTEASOME; PYRITHIONE; ZINC; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; THIOKETONE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL DEATH; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; LYSOSOME; METAL BINDING; NONHUMAN; REVIEW; STRUCTURE ANALYSIS; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CHELATING AGENTS; CLIOQUINOL; HUMANS; IONOPHORES; LYSOSOMES; METALS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRIDINES; THIONES; ZINC;

EID: 77449146289     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.253     Document Type: Review

References (56)

1. Beyersmann, D., and Haase, H. (2001) Functions of zinc in signaling, proliferation and differentiation of mammalian cells. Biometals 14, 331-341. (Pubitemid 34066636)
2. Chesters, J. K., Petrie, L., and Travis, A. J. (1990) A requirement for Zn2+ for the induction of thymidine kinase but not ornithine decarboxylase in 3T3 cells stimulated from quiescence. Biochem. J. 272, 525-527.
3. Chesters, J. K., Petrie, L., and Vint, H. (1989) Specificity and timing of the Zn2+ requirement for DNA synthesis by 3T3 cells. Exp. Cell. Res. 184, 499-508.
4. O'halloran, T. V. (1993) Transition metals in control of gene expression. Science 261, 715-725.
5. Cousins, R. J. (1994) Metal elements and gene expression. Annu. Rev. Nutr. 14, 449-469.
6. Jackson, K. A., Valentine, R. A., Coneyworth, L. J., Mathers, J. C., and Ford, D. (2008) Mechanisms of mammalian zinc-regulated gene expression. Biochem. Soc. Trans. 36, 1262-1266.
7. Berg, J. M., and Shi, Y. (1996) The galvanization of biology: a growing appreciation for the roles of zinc. Science. 271, 1081-1085.
8. Harrison, N. L., and Gibbons, S. J. (1994) Zn2+: an endogenous modulator of ligand- and voltage-gated ion channels. Neuropharmacology 33, 935-952. (Pubitemid 24290521)
9. Crapo, J. D., Oury, T., Rabouille, C., Slot, J. W., and Chang, L. Y. (1992) Copper,zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc. Natl. Acad. Sci. USA 89, 10405-10409.
10. Xu, J., Xu, Y., Nguyen, Q., Novikoff, P. M., and Czaja, M. J. (1996) Induction of hepatoma cell apoptosis by c-myc requires zinc and occurs in the absence of DNA fragmentation. Am. J. Physiol. 270, G60-G70.
11. Kim, Y. H., Kim, E. Y., Gwag, B. J., Sohn, S., and Koh, J. Y. (1999) Zinc-induced cortical neuronal death with features of apoptosis and necrosis: mediation by free radicals. Neuroscience 89, 175-182. (Pubitemid 29049037)
12. Adebodun, F., and Post, J. F. (1995) Role of intracellular free Ca(II) and Zn(II) in dexamethasone-induced apoptosis and dexamethasone resistance in human leukemic CEM cell lines. J. Cell. Physiol. 163, 80-86.
13. Zalewski, P. D., Forbes, I. J., and Betts, W. H. (1993) Correlation of apoptosis with change in intracellular labile Zn(II) using zinquin [(2-methyl-8-p-toluenesulphonamido-6-quinolyloxy)acetic acid], a new specific fluorescent probe for Zn(II). Biochem. J. 296, 403-408.
14. Lovejoy, D. B., and Richardson, D. R. (2003) Iron chelators as antineoplastic agents: current developments and promise of the PIH class of chelators. Curr. Med. Chem. 10, 1035-1049.
15. Brewer, G. J., Dick, R. D., Grover, D. K., Leclaire, V., Tseng, M., Wicha, M., Pienta, K., Redman, B. G., Jahan, T., Sondak, V. K., Strawderman, M., Lecarpentier, G., and Merajver, S. D. (2000) Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin. Cancer. Res. 6, 1-10.
16. Redman, B. G., Esper, P., Pan, Q., Dunn, R. L., Hussain, H. K., Chenevert, T., Brewer, G. J., and Merajver, S. D. (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin. Cancer. Res. 9, 1666-1672.
17. Ding, W. Q., Yu, H. J., and Lind, S. E. (2008) Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer. Lett. 271, 251-259.
18. Canzoniero, L. M., Manzerra, P., Sheline, C. T., and Choi, D. W. (2003) Membrane-permeant chelators can attenuate Zn2+-induced cortical neuronal death. Neuropharmacology 45, 420-428. (Pubitemid 36836138)
19. Lecane, P. S., Karaman, M. W., Sirisawad, M., Naumovski, L., Miller, R. A., Hacia, J. G., and Magda, D. (2005) Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer. Res. 65, 11676-11688.
20. Sahoo, S. K., Sawa, T., Fang, J., Tanaka, S., Miyamoto, Y., Akaike, T., and Maeda, H. (2002) Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 13, 1031-1038.
21. Kim, C. H., Kim, J. H., Hsu, C. Y., and Ahn, Y. S. (1999) Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-kappaB activation. FEBS. Lett. 449, 28-32.
22. Kim, C. H., Kim, J. H., Moon, S. J., Chung, K. C., Hsu, C. Y., Seo, J. T., and Ahn, Y. S. (1999) Pyrithione, a zinc ionophore, inhibits NF-kappaB activation. Biochem. Biophys. Res. Commun. 259, 505-509.
23. Magda, D., Lecane, P., Wang, Z., Hu, W., Thiemann, P., Ma, X., Dranchak, P. K., Wang, X., Lynch, V., Wei, W., Csokai, V., Hacia, J. G., and Sessler, J. L. (2008) Synthesis and anticancer properties of watersoluble zinc ionophores. Cancer. Res. 68, 5318-5325.
24. Lind, S. E., Park, J. S., and Drexler, J. W. (2009) Pyrithione and 8-hydroxyquinolines transport lead across erythrocyte membranes. Transl. Res. 154, 153-159.
25. Ding, W. Q., Liu, B., Vaught, J. L., Yamauchi, H., and Lind, S. E. (2005) Anticancer activity of the antibiotic clioquinol. Cancer. Res. 65, 3389-3395.
26. Yu, H., Zhou, Y., Lind, S. E., and Ding, W. Q. (2009) Clioquinol targets zinc to lysosomes in human cancer cells. Biochem. J. 417, 133-139.
27. Hamidinia, S. A., Shimelis, O. I., Tan, B., Erdahl, W. L., Chapman, C. J., Renkes, G. D., Taylor, R. W., and Pfeiffer, D. R. (2002) Monensin mediates a rapid and selective transport of Pb(2+). Possible application of monensin for the treatment of Pb(2+) intoxication. J. Biol. Chem. 277, 38111-38120.
28. Grafe, U., Schade, W., Roth, M., Radics, L., Incze, M., and Ujszaszy, K. (1984) Griseochelin, a novel carboxylic acid antibiotic from Streptomyces griseus. J. Antibiot. (Tokyo). 37, 836-846.
29. Brooks, H. A., Gardner, D., Poyser, J. P., and King, T. J. (1984) The structure and absolute stereochemistry of zincophorin (antibiotic M144255): a monobasic carboxylic acid ionophore having a remarkable specificity for divalent cations. J. Antibiot. (Tokyo). 37, 1501-1504.
30. Bessho, R., Matsubara, K., Kubota, M., Kuwakado, K., Hirota, H., Wakazono, Y., Lin, Y. W., Okuda, A., Kawai, M., Nishikomori, R., and Heike, T. (1994) Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappa B (NF-kappa B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem. Pharmacol. 48, 1883-1889.
31. Tsai, J. C., Jain, M., Hsieh, C. M., Lee, W. S., Yoshizumi, M., Patterson, C., Perrella, M. A., Cooke, C., Wang, H., Haber, E., Schlegel, R., and Lee, M. E. (1996) Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J. Biol. Chem. 271, 3667-3670.
32. Chinery, R., Brockman, J. A., Peeler, M. O., Shyr, Y., Beauchamp, R. D., and Coffey, R. J. (1997) Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat. Med. 3, 1233-1241.
33. Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., and Dou, Q. P. (2005) Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast. Cancer. Res. 7, R897-R908.
34. Kim, C. H., Kim, J. H., Xu, J., Hsu, C. Y., and Ahn, Y. S. (1999) Pyrrolidine dithiocarbamate induces bovine cerebral endothelial cell death by increasing the intracellular zinc level. J. Neurochem. 72, 1586-1592.
35. Blatt, J., Taylor, S. R., and Kontoghiorghes, G. J. (1989) Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer. Res. 49, 2925-2927.
36. Kontoghiorghes, G. J., Piga, A., and Hoffbrand, A. V. (1986) Cytotoxic effects of the lipophilic iron chelator omadine. FEBS. Lett. 204, 208-212.
37. Kondoh, M., Tasaki, E., Araragi, S., Takiguchi, M., Higashimoto, M., Watanabe, Y., and Sato, M. (2002) Requirement of caspase and p38MAPK activation in zinc-induced apoptosis in human leukemia HL-60 cells. Eur. J. Biochem. 269, 6204-6211.
38. Kondoh, M., Tasaki, E., Takiguchi, M., Higashimoto, M., Watanabe, Y., and Sato, M. (2005) Activation of caspase-3 in HL-60 cells treated with pyrithione and zinc. Biol. Pharm. Bull. 28, 757-759.
39. Mann, J. J., and Fraker, P. J. (2005) Zinc pyrithione induces apoptosis and increases expression of Bim. Apoptosis. 10, 369-379.
40. Cahoon, L. (2009) The curious case of clioquinol. Nat. Med. 15, 356-359.
41. Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjogren, M., Wallin, A., Xilinas, M., and Gottfries, C. G. (2001) Treatment of Alzheimer's disease with clioquinol. Dement. Geriatr. Cogn. Disord. 12, 408-414.
42. Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., Macgregor, L., Kiers, L., Cherny, R., Li, Q. X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R. E., and Masters, C. L. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691.
43. Ding, W. Q., Vaught, J. L., Yamauchi, H., and Lind, S. E. (2004) Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol. Cancer. Ther. 3, 1109-1117.
44. Ding, W. Q., Liu, B., Vaught, J. L., Palmiter, R. D., and Lind, S. E. (2006) Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol. Cancer. Ther. 5, 1864-1872.
45. Tuller, E. R., Brook, A. L., Yu, H. J., Lou, J. R., Benbrook, D. M., and Ding, W. Q. (2009) PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochem. Pharmacol. 77, 1480-1486.
46. Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P., and Dou, Q. P. (2007) Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer. Res. 67, 1636-1644.
47. Mao, X., Li, X., Sprangers, R., Wang, X., Venugopal, A., Wood, T., Zhang, Y., Kuntz, D. A., Coe, E., Trudel, S., Rose, D., Batey, R. A., Kay, L. E., and Schimmer, A. D. (2009) Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia. 23, 585-590.
48. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., Laughton, K., Li, Q. X., Charman, S. A., Nicolazzo, J. A., Wilkins, S., Deleva, K., Lynch, T., Kok, G., Ritchie, C. W., Tanzi, R. E., Cappai, R., Masters, C. L., Barnham, K. J., and Bush, A. I. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
49. Andersson, D. A., Gentry, C., Moss, S., and Bevan, S. (2009) Clioquinol and pyrithione activate TRPA1 by increasing intracellular Zn2+. Proc. Natl. Acad. Sci. USA 106, 8374-8379.
50. White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M., Evin, G., Cherny, R. A., Hill, A. F., Barnham, K. J., Li, Q. X., Bush, A. I., and Masters, C. L. (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281, 17670-17680.
51. Lee, E. J., Lee, J. Y., Seo, S. R., and Chung, K. C. (2007) Overexpression of DSCR1 blocks zinc-induced neuronal cell death through the formation of nuclear aggregates. Mol. Cell. Neurosci. 35, 585-595.
52. Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., and Kohn, K. W. (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23, 2934-2949.
53. Du, T., Filiz, G., Caragounis, A., Crouch, P. J., and White, A. R. (2008) Clioquinol promotes cancer cell toxicity through tumor necrosis factor alpha release from macrophages. J. Pharmacol. Exp. Ther. 324, 360-367.
54. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., Wilson, J., and Ritchie, C. W. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet. Neurol. 7, 779-786.
55. Cen, D., Gonzalez, R. I., Buckmeier, J. A., Kahlon, R. S., Tohidian, N. B., and Meyskens, F. L. (2002) Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol. Cancer. Ther. 1, 197-204.
56. Shian, S. G., Kao, Y. R., Wu, F. Y., and Wu, C. W. (2003) Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol. Pharmacol. 64, 1076-1084.